CLL cells often acquire defects in p53 status and this becomes a common mechanism of drug resistance, and the ability to enhance and maintain p53 function would enable standard chemotherapeutics, a continued role in CLL. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.